ArticleThe Journal of biological chemistry2014
Alternative intronic polyadenylation generates the interleukin-6 trans-signaling inhibitor sgp130-E10.
Article in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Soluble Glycoprotein 130Fc Reduces Controlled Cortical Impact-Induced Cognitive Deficits in Rats.Neurotrauma reports · 2025Article
- IL-6 Signaling in Immunopathology: From Basic Biology to Selective Therapeutic Intervention.ImmunoTargets and therapy · 2025Review
- Exploratory assessment of the effect of systemic administration of soluble glycoprotein 130 on cognitive performance and chemokine levels in a mouse model of experimental traumatic brain injury.Journal of neuroinflammation · 2024Article
- Long-term increase in soluble interleukin-6 receptor levels in convalescents after mild COVID-19 infection.Frontiers in immunology · 2024Article
- Article
- A Hybrid Soluble gp130/Spike-Nanobody Fusion Protein Simultaneously Blocks Interleukin-6Journal of virology · 2022Article
- Pleiotropic, Unique and Shared Responses Elicited by IL-6 Family Cytokines in Human Vascular Endothelial Cells.International journal of molecular sciences · 2022Article
- Identification of IL-6 Signalling Components as Predictors of Severity and Outcome in COVID-19.Frontiers in immunology · 2022Article
- Exclusive inhibition of IL-6 trans-signaling by soluble gp130Cytokine: X · 2021Article
- Anti-Inflammatory Effect of Muscle-Derived Interleukin-6 and Its Involvement in Lipid Metabolism.International journal of molecular sciences · 2021Review
- Expression of Interleukin 6 signaling receptors in carotid atherosclerosis.Vascular medicine (London, England) · 2021Article
- Alternative Splicing: A New Cause and Potential Therapeutic Target in Autoimmune Disease.Frontiers in immunology · 2021Review
- Genomic Multiple Sclerosis Risk Variants Modulate the Expression of theFrontiers in immunology · 2021Article
- Cortical bone maturation in mice requires SOCS3 suppression of gp130/STAT3 signalling in osteocytes.eLife · 2020Article
- Analysis of the genetic variants associated with circulating levels of sgp130. Results from the IMPROVE study.Genes and immunity · 2020Article
- Alternative Polyadenylation Modification Patterns Reveal Essential Posttranscription Regulatory Mechanisms of Tumorigenesis in Multiple Tumor Types.BioMed research international · 2020Article
- Cleavage factor 25 deregulation contributes to pulmonary fibrosis through alternative polyadenylation.The Journal of clinical investigation · 2019Article
- Different Soluble Forms of the Interleukin-6 Family Signal Transducer gp130 Fine-tune the Blockade of Interleukin-6 Trans-signaling.The Journal of biological chemistry · 2016Article
- Peripheral and Central Administration of Soluble Glycoprotein 130 Improves Cognitive Outcomes Following Controlled Cortical Impact in Male Mice.Neurotrauma reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin (IL)-6 signals via a receptor complex composed of the signal-transducing β-receptor gp130 and the non-signaling membrane-bound or soluble IL-6 receptor α (IL-6R, sIL-6R), which is referred to as classic and trans-signaling, respectively. IL-6 trans-signaling is functionally associated with the development of chronic inflammatory diseases and cancer. Soluble gp130 (sgp130) variants are natural inhibitors of trans-signaling. Differential splicing yields sgp130 isoforms. Here, we describe that alternative intronic polyadenylation in intron 10 of the gp130 transcript results in a novel mRNA coding for an sgp130 protein isoform (sgp130-E10) of 70-80 kDa. The sgp130-E10 protein was expressed in vivo in human peripheral blood mononuclear cells. To assess the biological activity of sgp130-E10, we expressed this variant as Fc-tagged fusion protein (sgp130-E10Fc). Recombinant sgp130-E10Fc binds to a complex of IL-6 and sIL-6R, but not to IL-6 alone, and specifically inhibits IL-6 trans-signaling. Thus, it might play an important role in the regulation of trans-signaling in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.